BioLife Solutions (BLFS) Proxy filing summary

Executive summary

• Entered into a Merger Agreement for acquisition by Repligen, with each share to receive $11.25 in cash and 0.1442 shares of Repligen common stock.

• The merger involves a two-step process, resulting in BioLife becoming a wholly owned subsidiary of Repligen.

• The Hart-Scott-Rodino waiting period expired on September 3, 2026, clearing a key regulatory hurdle.

• Completion of the merger remains subject to customary closing conditions, including shareholder approval at a special meeting scheduled for October 5, 2026.

• Forward-looking statements highlight anticipated benefits, synergies, and potential risks associated with the merger.

Voting matters and shareholder proposals

• Shareholders are to vote on the adoption of the Merger Agreement at a special meeting held remotely on October 5, 2026.

• Proxy materials and a prospectus have been or will be mailed to shareholders, urging them to review all documents before voting.

Board of directors and corporate governance

• Directors and executive officers of both companies may be deemed participants in the proxy solicitation for the merger.

• Information about directors and executive officers is available in annual reports and SEC filings.